Rheumatoid arthritis
Conditions
Interventions
Treatment group receiving Adalimumab (SCT630):NA
Sponsors
The First Affiliated Hospital of Xi'an Jiaotong University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) Age = 18 years old, regardless of gender; (2) Clinically diagnosed as rheumatoid arthritis (RA); (3) Doctor's prescription: Adalimumab injection (SCT630); (4) Ability to complete research related evaluations and records; (5) Volunteer to participate in the study and sign an informed consent form.
Exclusion criteria
Exclusion criteria: Patients who meet any of the following criteria will be excluded from this trial : ( 1 ) known to be allergic to adalimumab or preparation excipients ; ( 2 ) Patients who had previously been treated with adalimumab and were ineffective ; ( 3 ) active tuberculosis or other serious infectious diseases ; ( 4 ) patients with moderate to severe heart failure ( NYHA grade III / IV ) ; ( 5 ) patients with malignant tumor ; ( 6 ) pregnant or lactating women ; ( 7 ) Other situations judged by the researchers not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health Assessment Questionnaire,HAQ; | — |
Secondary
| Measure | Time frame |
|---|---|
| American Society of Rheumatology (ACR) 20 Response RateAmerican Society of Rheumatology (ACR) 20 Response Rate;ACR50 response rate;Number of tenderness joints;Number of swollen joints;C-reactive protein;Erythrocyte sedimentation;Rheumatoid arthritis disease activity score (DAS28); | — |
Countries
China
Contacts
Public ContactLan He
The First Affiliated Hospital of Xi'an Jiaotong University
Outcome results
None listed